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Aim To investigate whether or not key populations affected 
by hepatitis B and hepatitis C are being tested sufficiently 
for these diseases throughout the European region.
Methods We searched MEDLINE and EMBASE for stud-
ies on HBV and HCV testing in the 53 Member States of 
the World Health Organization European Region following 
PRISMA criteria.
Results 136 English-language studies from 24 countries 
published between January 2007 and June 2013 were 
found. Most studies took place in 6 countries: France, Ger-
many, Italy, the Netherlands, Turkey, and the United King-
dom. 37 studies (27%) addressed HBV, 46 (34%) HCV, and 53 
(39%) both diseases. The largest categories of study popu-
lations were people who use drugs (18%) and health care 
patient populations (17%). Far fewer studies focused on mi-
grants, prison inmates, or men who have sex with men. 
Conclusions The overall evidence base on HBV and HCV 
testing has considerable gaps in terms of the countries 
and populations represented and validity of testing uptake 
data. More research is needed throughout Europe to guide 
efforts to provide testing to certain key populations.
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The World Health Organization (WHO) has estimated that 
globally 240 million people are chronically infected with 
the hepatitis B virus (HBV) (1), and 130 to 150 million with 
the hepatitis C virus (HCV) (2). According to Global Bur-
den of Disease study findings, in 2010, hepatitis B caused 
almost 800 000 deaths and hepatitis C almost 500 000 
deaths (3) – more than AIDS, tuberculosis, or malaria. Most 
of these deaths resulted from liver cirrhosis and liver can-
cer, both of which are common outcomes of long-term 
HBV and HCV infection.
Although the WHO European Region accounts for only a 
small proportion of the overall global burden of hepatitis B 
and C, both diseases are recognized as major public health 
threats within this region (4,5). A recent review estimated 
that 13.3 million adults in the WHO European Region are 
positive for hepatitis B surface antigen (HBsAg), a figure 
representing 1.8% of the adult population (6). It is estimat-
ed that adult hepatitis C RNA (HCV RNA) prevalence is 15.0 
million, or 2.0% of the adult population.
The prevalence of HBV and HCV varies greatly across Euro-
pean countries, although gaps in the data and variations 
in study methodology hinder efforts to make reliable com-
parisons. HBsAg prevalence levels are reported to range 
from 0.1% (Ireland, the Netherlands) to 13.3% (Uzbekistan) 
(6). HCV RNA prevalence levels from 0.4% (Austria, Cyprus, 
Denmark, France, Germany, and the United Kingdom) to 
2.9% (Romania) have been noted (7). Within the Europe-
an Union, countries in the south and east appear to have 
lower HBV and HCV prevalence overall than countries in 
the northwest (8).
Among the populations thought to be heavily affected by 
one or more forms of viral hepatitis in Europe, the World 
Health Organization identifies people who inject drugs 
(PWID) as “the key risk group for HCV infection in most Eu-
ropean countries,” and also calls for attention to be given to 
men who have sex with men (MSM) engaging in high-risk 
behavior (9). Migrants are another population of concern 
in the region (6,10,11), as are prison inmates (12,13).
The field of viral hepatitis has seen important biomedical 
advances in recent years. The best antiviral drugs on the 
market can reduce severe consequences of chronic HBV in-
fection (14) and can cure most cases of HCV (15). While the 
high cost of these drugs has raised concerns about their 
affordability, this is not the only obstacle to treating more 
people. The drugs are at risk of being greatly underutilized 
because most people who might benefit from them re-
main undiagnosed (16). An analysis of data from 7 Euro-
pean countries concluded that only 10 to 40% of people in 
those countries are aware of their HCV infection (17).
There are individual and public health benefits to learning 
one’s hepatitis B and C status. First, people who know they 
have one or both of these diseases can choose to make 
lifestyle changes to help protect the liver, such as no lon-
ger consuming alcohol (1). It is also crucial for more people 
with undiagnosed HBV and HCV to learn about their con-
dition as a prerequisite to becoming candidates for treat-
ment. Diagnosis of HBV and HCV has important prevention 
implications as well. Through prevention education, peo-
ple infected with both diseases can learn how to take mea-
sures to avoid onward transmission. HCV-infected people 
who undergo treatment and achieve a cure are no longer 
at risk of spreading HCV to others.
Surveying the existing published knowledge on this topic 
to try to gain a better understanding of testing in Europe is 
an important preliminary step in strengthening the public 
health response to the challenges of reducing the number 
of undiagnosed infections and engaging more people in 
treatment. The aim of this scoping review is to investigate 
whether or not key populations affected by hepatitis B and 
hepatitis C in Europe are being tested sufficiently for these 
diseases throughout the region.
MethodS
A systematic literature review was conducted on hepati-
tis B and C testing in the 53 Member States of the WHO 
European Region. The MEDLINE and EMBASE databases 
were searched for articles and conference abstracts pub-
lished between 1 January 2007 and 30 June 2013. There 
was no limit set for the year of data collection. Keywords 
and medical subject headings (MeSH) for viral hepatitis B 
and C, testing and geographical scope were included in 
a broad search string (Supplementary material 1). The lit-
erature search was designed to identify English-language 
primary research articles and conference abstracts report-
ing on testing for hepatitis B or C in Europe. The protocol 
for this review was consistent with PRISMA criteria and was 
adapted from an earlier study that our group did on HCV 
among people who inject drugs (18,19).
Study selection
The screening process for study selection is shown 
in Figure 1. Following the MEDLINE and EMBASE 
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searches, duplicate results were removed and the titles 
and abstracts of the remaining results were screened in-
dependently by two researchers (IS and JVL) to determine 
whether studies presented data on hepatitis testing in Eu-
rope. The same two researchers then reviewed the full text 
of the 301 articles identified through this process to deter-
mine which ones met the selection criteria. In order to be 
included, studies needed to report on the number and pro-
portion of study participants tested for viral hepatitis. Stud-
ies were excluded if they focused on diagnostic aspects of 
viral hepatitis testing, if they reported data on pooled sam-
ples only, or if they involved the testing of deceased peo-
ple, organ or tissue donors, or already-diagnosed individu-
als. Studies that utilized multiple contemporary samples 
from the same person also were excluded. If two or more 
studies reported on the same study population, then only 
the most recently published study was retained.
data extraction
Data were extracted and inserted into an Excel spread-
sheet for further analysis using basic statistical methods. 
These data included study country; study design; study 
sample size; study setting; key characteristics of the study 
population; number and proportion of study participants 
tested for viral hepatitis; type of viral hepatitis that test-
ing was intended to detect (hepatitis B, hepatitis C, or 
both); viral hepatitis prevalence level or levels for those 
who were tested; and reported testing barriers. Decisions 
about which data to extract were guided by the criteria 
described in Box 1.
Box 1. data extraction criteria
• If a study reported pre- and post-intervention data, 
then only the pre-intervention (baseline) data were ex-
tracted.
• If a study reported on a longitudinal cohort with data 
available for multiple time points, then only the baseline 
data were extracted.
• If a study reported on multiple sequential cross-sec-
tional study populations, then only data for the most re-
cent study population were extracted.
Studies were sorted into separate categories on the basis 
of the type of study population. If a study met the criteria 
for being grouped with more than one type of popula-
tion, it was placed in the category most closely associ-
ated with its primary focus. If a study cohort could be 
disaggregated into multiple population categories, then 
findings for the different populations were reported sepa-
rately. Studies with study populations comprised of people 
living with HIV as well as studies pertaining to pregnancy 
and assisted reproductive technology were assessed sepa-
rately from other patient studies because of the large num-
bers of studies in these subgroups of patients.
ReSuLtS
The review identified 136 studies from 24 of the WHO Eu-
ropean Region’s 53 Member States (Figure 2, Figure 3). The 
countries with the largest numbers of studies were the 
United Kingdom (n=31), the Netherlands (n=18), France 
(n=12), Italy (n=12), and Germany (n=10). 37 (27.2%) stud-
ies addressed HBV, 46 (33.8%) addressed HCV, and 53 
(39.0%) addressed both diseases. Studies were grouped 
into 12 study population categories (Figure 4). The pop-
ulations most often studied were people who use drugs 
(17.6%), health care patient populations (16.9%), and peo-
ple tested for reasons relating to pregnancy or use of as-
sisted reproductive technology (11.5%). Although studies 
appeared in 78 different journals, 5 journals collectively 
accounted for one-quarter (27.2%) of studies: the Journal 
of Viral Hepatitis (n=15); Epidemiology and Infection (n=5); 
the Journal of Hepatology (n=6); the Journal of Medical Vi-
FIguRe 1. Study selection process.
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rology (n=5); and the European Journal of Gastroenterology 
and Hepatology (n=5). There was considerable variation in 
the number of studies published per year, with no obvious 
temporal trends.
136 studies were included in the analysis of studies 
grouped by study populations (20-156) (Supplementa-
ry material 2). Table 1 summarizes key findings for the 12 
study populations.
dIScuSSIon
Our review of hepatitis B and C testing research identified 
136 studies from 24 of the 53 countries of the WHO Europe-
an Region. The study populations most frequently studied 
were people who use drugs, health care patient popula-
tions, and people tested for reasons relating to pregnancy 
or use of assisted reproductive technology.
This review found a highly uneven distribution of HBV and 
HCV testing-related research outputs across the countries 
of the WHO European Region. 6 countries accounted for 
more than two-thirds of the studies included in the re-
view, and the United Kingdom alone accounted for al-
most one-quarter of studies. Furthermore, there appears 
to be a concentration of research activity in the countries 
of the European Union/European Free Trade Association 
(EU/EFTA). The only countries outside of this area with 
studies included in the review were Albania (2 studies), Is-
rael (2 studies), the Former Yugoslav Republic of Macedo-
nia (2 studies), and Turkey (9 studies). For some countries 
with high estimated HBV or HCV prevalence, such as Ro-
mania, Ukraine, and the Russian Federation (6), we failed 
to identify any studies that met review inclusion criteria.
Also, much of the research about some key populations 
is reported by a relatively small number of countries. For 
example, the 26 studies reporting on HBV/HCV testing in 
people who use drugs are from 9 countries, and 12 are 
from 1 country (the United Kingdom). While the English-
language restriction that our review employed may ac-
count for some of this imbalance, the review findings 
nonetheless raise the question of whether there might be 
knowledge gaps hampering an effective response to HBV 
and HCV in many European countries.
Although not the main objective of the study, we found 
median proportions of study participants tested for HBV 
or HCV to be 100% across most categories of study pop-
ulations. At the same time, some categories in which the 
median proportion tested was 100% also included studies 
that reported relatively low levels of testing. For example, 
33.6% of study participants in a study of people who use 
drugs were tested for HBV (39), and 13.0% of study partici-
pants in a study of asymptomatic patients in genitourinary 
FIguRe 2. geographical distribution of studies included in the review.
FIguRe 3. country settings for studies included in the review.
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medicine clinics were tested for HCV (59). However, we be-
lieve that our review findings around testing uptake are 
of limited value in assessing testing uptake levels in these 
populations because few studies had the specific purpose 
of examining HBV and HCV testing uptake. Most instead 
focused on measuring HBV and HCV prevalence. In many 
studies with 100% testing uptake, testing was actually a re-
quirement for study enrolment.
This review identified only 9 studies reporting on HBV and 
HCV testing in migrant populations, which is a matter of 
concern since migration is an important factor in the Eu-
ropean hepatitis B and C epidemics. All 9 studies were 
from countries with large migrant populations (Germany, 
Greece, Italy, the Netherlands, and the United Kingdom) 
(157). The influx of migrants from countries with high 
HBV endemicity contributes considerably to the burden 
of chronic HBV in Europe, and chronic HBV levels of 3.7% 
to 6.9% have been found among migrants in 18 Europe-
an countries (158). HBsAg prevalence in 8 migrant stud-
ies identified by our review ranged from 0.6% to 11.7%. Far 
less evidence is available regarding migration and HCV, but 
studies from France, the Netherlands, Spain, and the Unit-
ed Kingdom suggest that migrant populations may ac-
count for a sizeable proportion of HCV cases (159). A 2013 
Dutch study that estimated an 0.2% national HCV anti-
body prevalence level indicated that the largest number 
of cases was in migrants from HCV-endemic countries, 
with fewer cases among PWID and MSM (160).
Study populations as they occur in the real world are com-
prised of people who belong to multiple overlapping 
population groups. Information about different types of 
demographic and behavioral factors may be required to 
contextualize findings relating to some specific groups. 
For example, one of the “people living with HIV” studies in 
this review found a 43.8% anti-HCV prevalence level in 48 
Bulgarian study participants. While it was a heterogeneous 
cohort, the authors noted that all of the study participants 
who tested positive for anti-HCV were young men with a 
history of both injecting drug use and imprisonment (108).
Similarly, prison populations and PWID populations may 
overlap considerably. Although imprisonment puts people 
at a high risk of HCV infection, this is through risky behaviors 
that take place before or during imprisonment such as in-
jecting drug use. While injecting drug use is likely to be the 
most common HCV transmission pathway among prison 
inmates, it is not the only one (161). This complex situation 
may be difficult to tease apart with existing evidence. Al-
though our review included 8 studies enrolling current and 
former prison inmates, and several of those studies report 
high levels of injecting drug use among study participants, 
only 1 provides disaggregated study results for inmates 
who are injecting drug users and those who are not (140).
Ultimately, more data will be needed to gain insight into 
large-scale patterns regarding who is being tested for HBV 
and HCV in European countries and why. The contribu-
FIguRe 4. number of studies reporting on each disease and proportion of studies by population categories in the review.
447Lazarus et al: Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed?
www.cmj.hr
tABLe 1. Key findings for study populations
Study number Study sample size % tested
hepatitis B surface antigen 
(hBsAg) prevalence
Anti-hepatitis c virus 
(hcV) prevalence
population countries of studies range median range median range (%) median (%) range (%) median (%)
Blood donors
(9 studies)
Albania
Germany
Italy
Poland
Turkey
Hepatitis 
B virus 
(HBV): 3
HCV: 1
HBV/ 
HCV: 5
801–148,320 30,716 100–100 100 0.1–9.1 
(N = 8)
1.1 
(N = 8)
0–0.5 
(N = 6)
0.2 
(N = 6)
Health care 
workers
(6 studies)
Germany
Greece
Netherlands
Poland
HBV: 1
HCV: 4
HBV/
HCV: 1
104–9029 572 100–100 100 0.5 
(N = 1)
0.5 
(N = 1)
1.4–1.7 
(N = 4)
1.4 
(N = 4)
Health care 
patients
(25 studies)
France
Germany
Greece
Italy
Macedonia
Netherlands
Poland
Spain
Sweden
Turkey
United 
Kingdom
HBV: 5
HCV: 11
HBV/ 
HCV: 9
25–90,424* 844* 13.0–100† 100† 0.1–6.2 
(N = 11)
1.0 
(N = 11)
0–31.5 
(N = 17)
1.1 
(N = 17)
People living 
with HIV
(10 studies)
Bulgaria
France
Germany
Netherlands
Slovenia
Switzerland
United 
Kingdom
HBV: 2
HCV: 4
HBV/ 
HCV: 4
48–31,765 770 60.8–100 100 2.1–6.5 
(N = 5)
3.9 
(N = 5)
4.4–43.8 
(N = 7)
10.7 
(N = 7)
Migrants
(9 studies)
Germany
Greece
Italy
Netherlands
United 
Kingdom
HBV: 2
HCV: 0
HBV/ 
HCV: 7
250–5000‡ 709‡ 0–100§ 99.3§ 0.6–11.7 
(N = 8)II
3.0
(N = 8)II
0.4–5.6
(N = 8)II
1.1
(N = 8)II
Men who 
have sex with 
men
(5 studies)
Belgium
Croatia
Italy
Netherlands
United 
Kingdom
HBV: 1
HCV: 2
HBV/ 
HCV: 2
74–5230 387 68.6–100 100 0.8–12.0 
(N = 2)
6.4
(N = 2)
0.7–1.2
(N = 2)
1.0
(N = 2)
People who 
use drugs
(26 studies)
Cyprus
Denmark
France
Israel
Italy
Netherlands
Sweden
Switzerland
United  
Kingdom
HBV: 1
HCV: 18
HBV/ 
HCV: 7
40–97,250¶ 661¶ 0–100** 100** 0–52.3
(N = 4)
4.8
(N = 4)
6.3–86.5 
(N = 21)
50.0
(N = 21)
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tABLe 1. Key findings for study populations
Study number Study sample size % tested
hepatitis B surface antigen 
(hBsAg) prevalence
Anti-hepatitis c virus 
(hcV) prevalence
population countries of studies range median range median range (%) median (%) range (%) median (%)
Current/
former prison 
inmates
(8 studies)
Bulgaria
France
Hungary
Italy
Portugal
United 
Kingdom
HBV: 0
HCV: 2
HBV/ 
HCV: 6
151–318,550 550 2.6–100†† 88.6†† 0.7–6.7 (N = 4) 1.4 (N = 4) 4.8–77.4 (N = 7) 28.6 (N = 7)
General 
population
(10 studies)
France
Greece
Italy
Turkey
United 
Kingdom
HBV: 3
HCV: 4
HBV/ 
HCV: 3
452–503,060 5057 100–100 100 0.5–2.5 (N = 4) 1.5 (N = 4) 1.0–5.5 (N = 4) 2.6 (N = 4)
Children born 
to HBsAg-pos-
itive mothers
(3 studies)
Italy
Netherlands
HBV: 3
HCV: 0
HBV/ 
HCV: 0
100–2657 2280 75.4–100 79.8 0.6–0.7 (N = 2) 0.7 (N = 2) – –
People tested 
for reasons 
relating to 
pregnancy or 
use of assisted 
reproductive 
technology
(17 studies)
Albania
Denmark
Germany
Greece
Ireland
Netherlands
Norway
Portugal
Switzerland
Turkey
United 
Kingdom
HBV: 12
HCV: 1
HBV/ 
HCV: 4
206–
190,141‡‡
3932‡‡ 16.5–100§§100§§ 0.1–7.3 (N = 11) 0.7 (N = 11) 0.2–0.9 (N = 4) 0.4 (N = 4)
Other 
populations
(20 studies)
Albania
France
Germany
Greece
Hungary
Italy
Netherlands
Poland
Spain
Turkey
United 
Kingdom
HBV: 10
HCV: 4
HBV/ 
HCV: 6
99–14,759II II 1000II II 3.7–100¶¶ 100¶¶ 0.1–11.9 
(N = 9)***
2.1 (N = 9)*** 0.1–64.3 
(N = 9)***
2.8 
(N = 9)***
*Based on 26 data points because one study reported separate study sample figures for hepatitis B virus (hBV) and hepatitis c virus (hcV).
†Based on 27 data points because two studies reported separate testing figures for hBV and hcV.
‡Based on 11 data points because one study reported separate study sample figures for multiple study arms.
§Based on 12 data points because (a) one study reported separate testing figures for hBV and hcV, and (b) one study reported separate testing 
figures for multiple study arms.
IIBased on 9 data points because one study reported separate prevalence figures for multiple study arms.
¶Based on 27 data points because one study reported separate study sample figures for hBV and hcV.
**Based on 28 data points because (a) one study reported separate testing figures for hBV and hcV, and (b) one study reported separate testing 
figures for multiple study arms.
††Based on 9 data points because one study reported separate testing figures for hBV and hcV.
‡‡Based on 18 data points because one study reported separate study sample figures for hBV and hcV.
§§Based on 19 data points because two studies reported separate testing figures for hBV and hcV.
II IIBased on 23 data points because two studies reported separate study sample figures for multiple study arms.
¶¶Based on 23 data points because two studies reported separate testing figures for multiple study arms.
***Based on 22 data points because one study reported separate prevalence figures for multiple study arms.
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tion of this scoping review is to reveal a lack of evidence 
in the published literature for three key populations in 
the European HBV and HCV epidemics: migrants, prison 
inmates, and men who have sex with men. Although a 
much larger number of studies focusing on people who 
inject drugs were identified, the concentration of this re-
search in a small number of countries suggests the pos-
sibility of major country-level knowledge gaps in many 
countries.
Limitations
This review is subject to several limitations. Since it includ-
ed only peer-reviewed studies and conference abstracts, 
publication bias may have significantly distorted the true 
picture regarding who is being tested for HBV and HCV, and 
in which settings. Reports from national agencies were not 
considered. These are likely to contribute substantially to 
the knowledge base regarding testing uptake. We recom-
mend additional research to review reports from nation-
al agencies and other gray literature. Further, only articles 
published in English were included in this review, which 
may have biased our country distributions. Literature re-
views of publications in other languages and of secondary 
literature that includes gray literature may help to provide 
a more complete picture. The diversity of study popula-
tions within population categories makes it challenging to 
interpret some of the review’s findings. Finally, there were 
major differences in sample sizes, which limits the compa-
rability of findings within and across study populations.
conclusions
This review identified a large number of studies on HBV 
and HCV testing in Europe, with a wide range of popula-
tions represented in those studies as well as a highly un-
even geographical distribution of studies across the coun-
tries of the WHO European Region. The overall evidence 
base on HBV and HCV testing in the WHO European Region 
appears to have considerable gaps, particularly regarding 
the situation in non-EU/EFTA countries and among mi-
grant populations, prison inmates and men who have sex 
with men. The evidence base might be expanded consid-
erably if key stakeholders were to coordinate studies of 
HBV and HCV testing behavior with national public health 
agencies. Finally, the issues associated with obtaining valid 
testing uptake data from controlled study situations sug-
gest a need for a different approach to measuring testing 
uptake. Data on self-reported testing history may provide 
important insights.
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